CCR2 and cancer: Antibody therapies targeting factors related to the accumulation of monocytes in tissues, such as CCL2/CCR2, and adhesion to vascular endothelial cells, such as CD11b, have also been attempted in animal cancer experiments and clinical studies of human cancer (Ahn et al., 2010[1]; Nywening et al., 2016[21]).